KR100832821B1 - 각막 상피 신장 촉진제 - Google Patents
각막 상피 신장 촉진제 Download PDFInfo
- Publication number
- KR100832821B1 KR100832821B1 KR1020027016164A KR20027016164A KR100832821B1 KR 100832821 B1 KR100832821 B1 KR 100832821B1 KR 1020027016164 A KR1020027016164 A KR 1020027016164A KR 20027016164 A KR20027016164 A KR 20027016164A KR 100832821 B1 KR100832821 B1 KR 100832821B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- corneal
- uridine
- corneal epithelial
- delete delete
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
약제 (농도) | 각막 상피 신장율(%) |
DUTP-Na (100 μM) | 118.9 |
UDP-Na (100 μM) | 115.3 |
ADP-Na (10 μM) | 116.1 |
UTP-Na (100 μM) | 123.1 |
ATP-Na (10 μM) | 119.3 |
대조 | 100.0 |
100 ㎖ 중 | |
DUTP-Na | 10 ㎎ |
염화나트륨 | 900 ㎎ |
멸균 정제수 | 적량 |
100 ㎖ 중 | |
UTP-Na | 100 ㎎ |
염화나트륨 | 800 ㎎ |
인산수소이나트륨 | 100 ㎎ |
인산이수소나트륨 | 적량 |
멸균 정제수 | 적량 |
100 g 중 | |
DUTP-Na | 0.3 g |
유동 파라핀 | 10.0 g |
백색 와세린 | 적량 |
100 g 중 | |
UDP-Na | 0.3 g |
유동 파라핀 | 10.0 g |
백색 와세린 | 적량 |
Claims (9)
- P2Y 수용체 작용물질을 유효 성분으로 하는 각막 상피의 신장을 촉진하는 것에 의한 각막 궤양, 각막 상피 박리, 각막염 또는 안구 건조증 치료제로서, 상기 P2Y 수용체 작용물질이 하기 화학식 I로 표시되는 화합물 또는 이의 염류인 것인 각막 궤양, 각막 상피 박리, 각막염 또는 안구 건조증 치료제:화학식 I상기 화학식에서, n은 1∼4의 정수이고, X는 수소 원자 또는 하기 화학식 II로 표시되는 기를 나타내며,화학식 IIR1 및 R2는 동일하거나 또는 상이하며, 우라실기, 티밀기, 아데닐기, 크산틸기 또는 구아닐기를 각각 나타낸다.
- 제1항에 있어서, P2Y 수용체 작용물질이 P1,P4-디(우리딘-5')사인산, 우리딘 5'-이인산, 아데노신 5'-이인산, 우리딘 5'-삼인산 또는 아데노신 5'-삼인산 또는 이의 염류인 것인 각막 궤양, 각막 상피 박리, 각막염 또는 안구 건조증 치료제.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000159889 | 2000-05-30 | ||
JPJP-P-2000-00159889 | 2000-05-30 | ||
PCT/JP2001/004520 WO2001091795A1 (fr) | 2000-05-30 | 2001-05-30 | Promoteurs de l'extension de l'epithelium corneen |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030031489A KR20030031489A (ko) | 2003-04-21 |
KR100832821B1 true KR100832821B1 (ko) | 2008-05-28 |
Family
ID=18664160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027016164A KR100832821B1 (ko) | 2000-05-30 | 2001-05-30 | 각막 상피 신장 촉진제 |
Country Status (9)
Country | Link |
---|---|
US (2) | US6984629B2 (ko) |
EP (1) | EP1428538B1 (ko) |
KR (1) | KR100832821B1 (ko) |
CN (1) | CN100391538C (ko) |
AU (2) | AU2001260643B9 (ko) |
BR (1) | BR0111297A (ko) |
CA (1) | CA2413928C (ko) |
MX (1) | MXPA02011710A (ko) |
WO (1) | WO2001091795A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101875845B1 (ko) * | 2012-03-26 | 2018-07-06 | 산텐 세이야꾸 가부시키가이샤 | 디쿠아포솔 함유 점안액 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6864243B1 (en) * | 2000-05-12 | 2005-03-08 | Inspire Pharmaceuticals, Inc. | Method for treating retinal degeneration with purinergic receptor agonists |
JP4313033B2 (ja) | 2002-12-27 | 2009-08-12 | 株式会社日本点眼薬研究所 | 眼科用治療組成物 |
TW201306844A (zh) * | 2010-12-28 | 2013-02-16 | 參天製藥股份有限公司 | 含有迪夸弗索點眼液及其製造方法、不溶性析出物產生之抑制方法 |
EA202092030A1 (ru) * | 2018-02-28 | 2020-11-16 | Сантен Фармасьютикал Ко., Лтд. | Офтальмологическая композиция, включающая диквафозол и катионный полимер |
CN117771172A (zh) * | 2019-08-27 | 2024-03-29 | 参天制药株式会社 | 含有地夸磷索或其盐、及聚乙烯吡咯烷酮的水性眼科用组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5900407A (en) * | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292498A (en) * | 1991-06-19 | 1994-03-08 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
PT981534E (pt) | 1997-02-06 | 2006-09-29 | Inspire Pharmaceuticals Inc | Dinucleotidos e suas utilizacoes |
US6696425B2 (en) * | 1997-02-06 | 2004-02-24 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with purinergic receptor agonists |
JP4633927B2 (ja) | 1998-05-22 | 2011-02-16 | インスパイアー ファーマシューティカルズ,インコーポレイティド | 治療用ジヌクレオチドおよび誘導体 |
CA2359891A1 (en) * | 1999-02-26 | 2000-08-31 | Inspire Pharmaceuticals, Inc. | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
US6409175B1 (en) | 1999-07-13 | 2002-06-25 | Grant Prideco, Inc. | Expandable joint connector |
-
2001
- 2001-05-30 AU AU2001260643A patent/AU2001260643B9/en not_active Expired
- 2001-05-30 US US10/297,233 patent/US6984629B2/en not_active Expired - Lifetime
- 2001-05-30 WO PCT/JP2001/004520 patent/WO2001091795A1/ja active Application Filing
- 2001-05-30 MX MXPA02011710A patent/MXPA02011710A/es active IP Right Grant
- 2001-05-30 EP EP01934399.5A patent/EP1428538B1/en not_active Expired - Lifetime
- 2001-05-30 CN CNB018102328A patent/CN100391538C/zh not_active Expired - Lifetime
- 2001-05-30 KR KR1020027016164A patent/KR100832821B1/ko active IP Right Review Request
- 2001-05-30 AU AU6064301A patent/AU6064301A/xx active Pending
- 2001-05-30 BR BR0111297-0A patent/BR0111297A/pt not_active Application Discontinuation
- 2001-05-30 CA CA2413928A patent/CA2413928C/en not_active Expired - Lifetime
-
2005
- 2005-09-07 US US11/222,167 patent/US20060009415A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5900407A (en) * | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101875845B1 (ko) * | 2012-03-26 | 2018-07-06 | 산텐 세이야꾸 가부시키가이샤 | 디쿠아포솔 함유 점안액 |
US10071113B2 (en) | 2012-03-26 | 2018-09-11 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solution comprising diquafosol |
KR101935484B1 (ko) | 2012-03-26 | 2019-01-04 | 산텐 세이야꾸 가부시키가이샤 | 디쿠아포솔 함유 점안액 |
US10632139B2 (en) | 2012-03-26 | 2020-04-28 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solution comprising diquafosol |
US11166974B2 (en) | 2012-03-26 | 2021-11-09 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solution comprising Diquafosol |
Also Published As
Publication number | Publication date |
---|---|
EP1428538A1 (en) | 2004-06-16 |
CN100391538C (zh) | 2008-06-04 |
AU6064301A (en) | 2001-12-11 |
EP1428538B1 (en) | 2013-08-14 |
KR20030031489A (ko) | 2003-04-21 |
AU2001260643B9 (en) | 2006-10-19 |
BR0111297A (pt) | 2004-01-06 |
CA2413928C (en) | 2011-01-25 |
AU2001260643B2 (en) | 2006-06-08 |
US20030186927A1 (en) | 2003-10-02 |
EP1428538A4 (en) | 2006-04-05 |
WO2001091795A1 (fr) | 2001-12-06 |
CN1431914A (zh) | 2003-07-23 |
MXPA02011710A (es) | 2004-07-30 |
US20060009415A1 (en) | 2006-01-12 |
US6984629B2 (en) | 2006-01-10 |
CA2413928A1 (en) | 2001-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100315612B1 (ko) | N-알킬-2-치환아데노신트리포스페이트동족체 | |
US6624150B2 (en) | Method of treating gastrointestinal tract disease with purinergic receptor agonists | |
US5900407A (en) | Method of treating dry eye disease with uridine triphosphates and related compounds | |
WO2012033189A1 (ja) | P2y2受容体作動薬およびヒアルロン酸またはその塩を組み合わせたことを特徴とするドライアイ治療剤、ドライアイの治療方法、ならびにその使用 | |
CN103687866A (zh) | 用于治疗病毒性感染的嘌呤单磷酸酯前药 | |
US20040063651A1 (en) | Remedies for hepatitis c | |
JP2004533406A (ja) | ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド | |
US20070197454A1 (en) | P1-(2'-deoxycytidine 5'-)p4-(uridine 5'-)tetraphosphate, tetra-(alkali metal) salt, for treating disorders | |
CZ301169B6 (cs) | Použití nukleosidového derivátu pro výrobu léciva pro lécení hepatitidy C | |
KR100832821B1 (ko) | 각막 상피 신장 촉진제 | |
EP0409227A2 (de) | Pyrimidinnucleoside, ihre Herstellung und pharmazeutische Mittel | |
MXPA02008827A (es) | Metodo para tratar la degeneracion retinal con agonistas de los receptores purinergicos. | |
KR100618028B1 (ko) | 항-b형 간염 활성을 가진 뉴클레오시드 | |
JP4003008B2 (ja) | 角膜上皮伸展促進剤 | |
KR20020069218A (ko) | 퓨린성 수용체 작동제에 의한 위장관 질환 치료 방법 | |
US7084128B2 (en) | Method for reducing intraocular pressure | |
Maudgal et al. | Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents | |
PT90475B (pt) | Processo para a preparacao de pro-farmacos de 2',3'-didehidro-2',3'-didesoxinucleosidos com accao anti-viral | |
EP4218938A1 (en) | Treatment of mitochondrial diseases | |
KR960002739B1 (ko) | 각막 장해 치료제 | |
WO2015165975A1 (en) | Methods and compositions for treating myeloid neoplasias | |
CA2054771A1 (en) | Method of treatment of hepatitis | |
WO1995010287A1 (en) | Substituted purine nucleoside analogs and method for treating endotoxin shock | |
Keppeler et al. | Syntheses and Antiviral Activities of Some 5′‐O‐Acyl Derivatives | |
JPH0361646B2 (ko) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
A101 | Application to extend term of patent right by permit | ||
FPAY | Annual fee payment |
Payment date: 20130503 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140502 Year of fee payment: 7 |
|
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
FPAY | Annual fee payment |
Payment date: 20150416 Year of fee payment: 8 |
|
J501 | Disposition of invalidation of trial | ||
J501 | Disposition of invalidation of trial | ||
J121 | Written withdrawal of request for trial | ||
J501 | Disposition of invalidation of trial | ||
J121 | Written withdrawal of request for trial | ||
J501 | Disposition of invalidation of trial | ||
J121 | Written withdrawal of request for trial | ||
FPAY | Annual fee payment |
Payment date: 20160419 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170420 Year of fee payment: 10 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2015100001909; TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150403 Effective date: 20170523 Free format text: TRIAL NUMBER: 2015100001280; TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150320 Effective date: 20170523 Free format text: TRIAL NUMBER: 2015100001906; TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150403 Effective date: 20170523 Free format text: TRIAL NUMBER: 2015100002021; TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150403 Effective date: 20170523 Free format text: TRIAL NUMBER: 2015100001285; TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150320 Effective date: 20170523 Free format text: TRIAL NUMBER: 2015100001279; TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150320 Effective date: 20170523 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2015100001172; TRIAL DECISION FOR INVALIDATION REQUESTED 20150320 Effective date: 20171228 Free format text: TRIAL NUMBER: 2015100001171; TRIAL DECISION FOR INVALIDATION REQUESTED 20150320 Effective date: 20171228 Free format text: TRIAL NUMBER: 2015100001644; TRIAL DECISION FOR INVALIDATION REQUESTED 20150328 Effective date: 20171228 Free format text: TRIAL NUMBER: 2015100001846; TRIAL DECISION FOR INVALIDATION REQUESTED 20150402 Effective date: 20171228 Free format text: TRIAL NUMBER: 2015100001166; TRIAL DECISION FOR INVALIDATION REQUESTED 20150320 Effective date: 20171228 Free format text: TRIAL NUMBER: 2015100001519; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20171228 Free format text: TRIAL NUMBER: 2015100001901; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403 Effective date: 20171228 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2015100001850; TRIAL DECISION FOR INVALIDATION REQUESTED 20150402 Effective date: 20180122 |
|
J202 | Request for trial for correction [limitation] | ||
FPAY | Annual fee payment |
Payment date: 20180417 Year of fee payment: 11 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2018105000037; TRIAL DECISION FOR CORRECTION REQUESTED 20180326 Effective date: 20180716 |
|
J2X1 | Appeal (before the patent court) |
Free format text: TRIAL NUMBER: 2018205006535; CORRECTION |
|
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2017200004525; JUDGMENT (PATENT COURT) FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20170629 Effective date: 20180810 |
|
J121 | Written withdrawal of request for trial | ||
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2018200002366; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20180226 Effective date: 20190201 Free format text: TRIAL NUMBER: 2018200002359; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20180226 Effective date: 20190201 Free format text: TRIAL NUMBER: 2018200002342; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20180226 Effective date: 20190201 Free format text: TRIAL NUMBER: 2018200002373; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20180226 Effective date: 20190201 |
|
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2018200002335; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20180226 Effective date: 20190201 |
|
G170 | Re-publication after modification of scope of protection [patent] | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
G170 | Re-publication after modification of scope of protection [patent] |